Breast MRI

Breast MRI
Breast MRI demonstrating marked enhancement (bright area) which was confirmed to be cancer.
ICD-10-PCSBH3
ICD-9-CM88.92, 88.97
OPS-301 code3-827

One alternative to mammography, Breast MRI or contrast enhanced magnetic resonance imaging (MRI), has shown substantial progress in the detection of breast cancer.

Indications

  • Screening for malignancy in women with greater than 20% lifetime risk of breast cancer.
  • Evaluate breast implants for rupture.
  • Screening the opposite side breast for malignancy in women with known one sided breast malignancy.
  • Extent of disease and the presence of multifocality and multicentricity in patients with invasive carcinoma and ductal carcinoma in situ (DCIS).
  • Evaluate response to neoadjuvant chemotherapy.

[1]

Comparison to other technologies

The available literature suggests that the sensitivity of contrast-enhanced breast MRI in detection of cancer is considerably higher than that of either radiographic mammography or ultrasound and is generally reported to be in excess of 94%.[2]

The specificity (the confidence that a lesion is cancerous and not a false positive) is only fair ('modest'),[3] (or 37–97%[2]) thus a positive finding by MRI should not be interpreted as a definitive diagnosis.

The reports of 4,271 breast MRIs from eight large scale clinical trials were reviewed in 2006.[4]

Nephrogenic systemic fibrosis

The systemic disease nephrogenic systemic fibrosis (NSF) resembles scleromyxedema and to some extent scleroderma. It may occur months after contrast has been injected. Patients with poorer kidney function are more at risk for NSF, with dialysis patients being more at risk than patients with chronic kidney disease. After several years of controversy during which up to 100 Danish patients have been gadolinium poisoned (and some died) after use of the contrast agent Omniscan, it was admitted by the Norwegian medical company Nycomed that they were aware of some dangers of using gadolinium-based agents for their product. At present, NSF has been linked to the use of four gadolinium-containing MRI contrast agents.

References

  1. ↑ "ACR Practice Parameter for the Performance of Contrast-Enhanced Magnetic Resonance Imaging (MRI) of the Breast" (PDF). American College of Radiology. 2013. Archived from the original (PDF) on 2017-06-23. Retrieved 2017-11-11.
  2. 1 2 Goscin, Christopher P.; Berman, Claudia G.; Clark, Robert A. (2001). "Magnetic Resonance Imaging of the Breast". Cancer Control. 8 (5): 399–406. doi:10.1177/107327480100800502. PMID 11579335.
  3. ↑ DeMartini W, Lehman C, Partridge S (April 2008). "Breast MRI for cancer detection and characterization: a review of evidence-based clinical applications". Acad Radiol. 15 (4): 408–16. doi:10.1016/j.acra.2007.11.006. PMID 18342764.
  4. ↑ Lehman CD (2006). "Role of MRI in screening women at high risk for breast cancer". Journal of Magnetic Resonance Imaging. 24 (5): 964–70. doi:10.1002/jmri.20752. PMID 17036340.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.